Associations of IgG N-linked oligosaccharide chains and proteases in sera of prostate cancer patients with and without α2-macroglobulin deficiency

Journal of Clinical Laboratory Analysis

Volumn 23, Issue 2, 2009, Pages 125-131

  Kanoh, Yuhsaku ^a,c   Egawa, Shin ^b   Baba, Shiro ^a   Akahoshi, Tohru ^a  

^a KITASATO UNIVERSITY   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

2 macroglobulin; Antigen; Matrix metalloproteinase 2; N linked oligosaccharides; Prostate specific

Indexed keywords

ALPHA 2 MACROGLOBULIN; ASPARAGINE LINKED OLIGOSACCHARIDE; GELATINASE A; IMMUNOGLOBULIN G; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; MALE; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY;

AGED; ALPHA-MACROGLOBULINS; HUMANS; IMMUNOGLOBULIN G; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; OLIGOSACCHARIDES; PEPTIDE HYDROLASES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 63149155634     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20302     Document Type: Article

References (27)

1. 2- macroglobulin deficiency in association with cancer metastasis. Jpn J Clin Immunol 1997;20:30-43.
2. Kanoh Y, Akahoshi T, Ohara T, et al. Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer. Anticancer Res 2002;22:1813-1818.
3. Kenneth WKW, Paul JL, Thabiso MT, Wai PC, Rueywing L. Human prostate-specific antigen: Structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986;83:3166-3170.
4. Uwe T, Thomas Q, Folkert D, Astrid L, Radoff D. Biological activity of prostate-specific antigen isolated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electroelution. Electrophoresis 1995;16:793-799.
5. 1-antichymotrypsin as indicator of prostate cancer. J Urol 1993;150:100-105.
6. 2 macroglobulin complexes in prostate cancer patient sera. Biochem Mol Biol Int 1995;37:917-923.
7. Smith DS, Humphrey PA, Catalona WJ. The early detection of prostate carcinoma with prostate specific antigen. Cancer 1997;80:1852-1856.
8. Stege R, Grande M, Carlstrom K. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinoma. Clin Cancer Res 2000;6:160-165.
9. D'Amico AV, Whittington R, Malkowicz SB. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 2000;18:1164-1172.
10. Klaus J, Brigitte B, Michael L, et al. Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: Biochemical and diagnostic implications. Clin Chem 2000;46:47-54.
11. Klaus J, Ulrike E, Michael L, et al. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: Which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer? Clin Chem 2000;46:55-62.
12. Festuccia C, Vincentini C, Di Pasquale A. Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma. Oncol Res 1995;7:131-138.
13. Quax PHA, Bart de ACW, Schalken JA, Verheijen JH. Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: Correlation with metastatic behavior in vivo. Prostate 1997;32:196-204.
14. Elise CK, Lance AL. Molecular insights into cancer invasion: Strategies for prevention and intervention. Cancer Res 1995;55:1856-1862.
15. Axford JS. Oligosaccharides. An optional extra of relevance to disease mechanisms in rheumatology? J Rheumatol 1991;18:1124-1127.
16. Adler Y, Lamour A, Jamin C. Impaired binding capacity of asialyl and agalactosyl IgG to Fc gamma receptors. Clin Exp Rheumatol 1995;13:315-319.
17. Mizuochi T, Hamako J, Nose M. Structural changes in the oligosaccharide chains of IgG in autoimmune MRL/Mp-lpr/lpr mice. J Immunol 1990;145:1794-1798.
18. Malhotra R, Wormald MR, Rudd PM. Glycosylation change of IgG associated complement via the mannose-binding protein. Nat Med 1995;1:238-243.
19. Kossowska B, Ferens-Sieczkowska M, Gancarz R. Fucosylation of serum glycoproteins in lung cancer patients. Clin Chem Lab Med 2005;43:361-369.
20. Kanoh Y, Mashiko T, Danbara M, et al. Analysis of the oligosaccharide chain of human serum immunoglobulin G in patients with localized or metastatic cancer. Oncology 2004;66:365-370.
21. Spiessl B, Beahrs OH, Hermane KP. International Union Against Cancer. TNM Atlas, third edition, second revision. New York: Springer, 1992. p 241-250.
22. Debanne MT, Regoeczl E, Dolovich J. Serum prostate inhibitors in the blood clearance of subtilisin A. Br J Exp Pathol 1973;54:571-582.
23. Katayama K, Fujita T. Studies on biotransformation of elastase III effects of elastase-binding proteins in serum on the disappearance of 131I-labeled elastase from blood. Biochim Biophys Acta 1973;336:165-177.
24. 2-macroglobulin, and their complexes. Oncol Rep 2001;8:515-519.
25. Zhong WD, Han ZD, He HC, et al. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer. Oncology 2008;75:230-236.
26. Hoikkala S, Paakko P, Soini Y, Makitaro R, Kinnula V, Turpeeniemi-Hujanen T. Tissue MMP-2 and MMP-9 are better prognostic factors than serum MMP-2/TIMP-2 complex or TIMP-1 in stage I-III lung carcinoma. Cancer Lett 2006;236:125-132.
27. Fujji S, Nishiura T, Nshikawa A, Miura R, Taniguchi N. Structural heterogeneity of sugar chains in immunoglobulin G. J Biol Chem 1990;265:6009-6018.